Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference11 articles.
1. Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453–65.
2. Freedland SJ, Gleave M, Giorgi UD, Rannikko A, Pieczonka CM, Tutrone RF, et al. Enzalutamide and quality of life in biochemically recurrent prostate cancer. NEJM Evid. 2023;2.
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9.
4. Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. 2014;66:204–10.
5. Urology EAo. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023: EAU Guidelines Office, Arnhem, The Netherlands; 2023. https://uroweb.org/guidelines/prostate-cancer.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献